Evommune, Inc. (NYSE:EVMN) Given Average Rating of “Moderate Buy” by Brokerages

Evommune, Inc. (NYSE:EVMN) has earned a consensus recommendation of “Moderate Buy” from the twelve analysts that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $45.7143.

EVMN has been the subject of a number of recent analyst reports. Weiss Ratings assumed coverage on shares of Evommune in a research note on Tuesday, February 3rd. They set a “sell (e)” rating for the company. Morgan Stanley assumed coverage on shares of Evommune in a research note on Monday, December 1st. They issued an “overweight” rating and a $36.00 target price for the company. Cantor Fitzgerald initiated coverage on shares of Evommune in a report on Monday, December 1st. They set an “overweight” rating for the company. Evercore started coverage on Evommune in a report on Monday, December 1st. They issued an “outperform” rating and a $40.00 price target for the company. Finally, Wall Street Zen raised Evommune from a “sell” rating to a “hold” rating in a research note on Sunday, December 14th.

Institutional Investors Weigh In On Evommune

Several large investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Evommune during the fourth quarter worth approximately $34,000. The Manufacturers Life Insurance Company purchased a new position in shares of Evommune in the 4th quarter valued at approximately $179,000. State Street Corp purchased a new position in Evommune in the 4th quarter valued at $539,000. TD Asset Management Inc purchased a new position in shares of Evommune during the 4th quarter worth approximately $764,000. Finally, Capricorn Fund Managers Ltd purchased a new position in shares of Evommune in the 4th quarter valued at about $1,027,000.

Evommune Stock Up 13.3%

Shares of EVMN stock opened at $31.60 on Friday. Evommune has a 12-month low of $13.89 and a 12-month high of $33.20. The company has a market capitalization of $996.03 million and a PE ratio of -3.92. The stock has a 50-day moving average price of $19.04.

Evommune (NYSE:EVMN) last announced its earnings results on Thursday, December 11th. The company reported ($8.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($6.58) by ($1.49). The firm had revenue of $10.00 million for the quarter, compared to analysts’ expectations of $10.00 million.

About Evommune

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.